Price, one year
Price range
- Open
- ₹2,848.90
- High
- ₹2,924.00
- Low
- ₹2,769.80
- Previous close
- ₹2,850.40
- Volume
- 4.2 L
- Market cap
- ₹46,645 Cr
Key statistics
Results to 30 Jun 2026 · Consolidated- P/E (TTM)
- 41.3
- Price to book
- 4.5
- Return on equity
- 10.9%
- EPS (TTM)
- ₹68.51
- Book value / share
- ₹627.71
- Debt to equity
- 0.02
- Revenue (TTM)
- ₹6,725 Cr
- Net profit (TTM)
- ₹1,129 Cr
- Sales growth, YoY
- +19.6%
- Profit growth, YoY
- +47.1%
- Operating margin
- 26.0%
- Net margin
- 16.8%
- Sales CAGR, 3 years
- +21.1%
- Profit CAGR, 3 years
- +9.6%
- Promoter holding
- 45.75%
- Promoter shares pledged
- 0.00%
Shareholding pattern
% of shares| Holder | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Promoters | 51.83 | 51.77 | 45.75 |
| Foreign institutions | 7.30 | 8.74 | 10.36 |
| Domestic institutions | 33.35 | 30.44 | 33.21 |
| Mutual funds | 31.78 | 28.23 | 29.52 |
| Retail and others | 2.54 | 3.50 | 4.63 |
Results and announcements
Latest results (quarter to 30 Jun 2026) filed 10 Aug 2026. results: 6 Nov 2026.
- 23 Oct 2026 · OtherGeneral UpdatesGland Pharma Limited has informed the Exchange about Conclusion of USFDA Unannounced Inspection at Company s Formulation Facility at Dundigal, Hyderabad
- 21 Oct 2026 · Investor meetAnalysts/Institutional Investor Meet/Con. Call UpdatesGland Pharma Limited has informed the Exchange about Schedule of meet
- 1 Oct 2026 · ManagementResignation of Director/KMP/SMPGland Pharma Limited has informed the Exchange about Resignation of Director/KMP/SMP
- 1 Oct 2026 · OtherGeneral UpdatesGland Pharma Limited has informed the Exchange about Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.
- 1 Oct 2026 · OtherOutcome of Board MeetingGland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026.
Peers in Healthcare
All Healthcare stocks| Company | Price | Change |
|---|---|---|
| Sun Pharmaceutical IndustriesSUNPHARMA | ₹1,748.00 | −0.57% |
| Divi's LaboratoriesDIVISLAB | ₹8,950.00 | −2.31% |
| Torrent PharmaceuticalsTORNTPHARM | ₹4,524.40 | −1.97% |
| Zydus LifesciencesZYDUSLIFE | ₹1,129.40 | −0.49% |
| Apollo Hospitals EnterpriseAPOLLOHOSP | ₹7,730.00 | +1.65% |
| CiplaCIPLA | ₹1,338.00 | +0.53% |
| Laurus LabsLAURUSLABS | ₹1,970.00 | −1.62% |
| Dr. Reddy's LaboratoriesDRREDDY | ₹1,229.50 | −0.77% |
| Mankind PharmaMANKIND | ₹2,212.60 | −2.77% |
| Aurobindo PharmaAUROPHARMA | ₹1,571.70 | −2.43% |
Frequently asked questions
What is the share price of Gland Pharma today?
Gland Pharma (NSE: GLAND) was at ₹2,826.80 on 23 Oct 2026, a change of −0.83% from the previous close.
What are the 52-week high and low of Gland Pharma?
Over the last 52 weeks Gland Pharma traded between ₹1,573.60 and ₹3,171.00 (daily highs and lows on NSE on 23 Oct 2026).
What is the market capitalisation of Gland Pharma?
About ₹46,645 Cr at the latest price, with a P/E of 41.3, a price-to-book of 4.5, a return on equity of 10.9%. Ratios use the company's latest reported results.
Who owns Gland Pharma shares?
According to the shareholding pattern filed with the exchange at the end of the quarter to 30 Sep 2026, promoters held 45.75%, foreign institutions 10.36%, domestic institutions 33.21%.
Which sector and indices does Gland Pharma belong to?
NSE classifies Gland Pharma under Healthcare; it is a member of Nifty 500.
Follow Gland Pharma with research you can verify. Add it to a watchlist, see screens and charts, and get calls from SEBI-registered research analysts with recorded track records.
Start free trial